

8 March 2022

Pharma enquiry – Rheumatology and Dermatology

Question 1.

How many patients were treated by your Trust in the last 3 months with the following drugs:

Rheumatology

Adalimumab (Amgevita)	Adalimumab (Humira)	Adalimumab (Hyrimoz)	Adalimumab (Idacio)	Adalimumab (Imraldi)
33	410	zero	zero	680

Dermatology

Adalimumab (Amgevita)	Adalimumab (Humira)	Adalimumab (Hyrimoz)	Adalimumab (Idacio)	Adalimumab (Imraldi)
40	45	zero	zero	118

Question 2.

Of the patients treated with Humira in the last 3 months, how many were new to Adalimumab treatment (patients who had **not** been treated with any brand of Adalimumab in the past year)? If possible please provide new patients number by:

New Humira patients – all departments	New Humira patients – rheumatology	New Humira patients – dermatology	New Humira patients – gastroenterology
	< 5	< 5	

Please note: Use of < 5 (less than five): We are unable to provide an exact figure - exempt from release under section 40(2) of the FOI Act - as this could make patients personally identifiable. Disclosure would constitute a breach of the principles of the General Data Protection Regulations 2018.

Question 3.

Of the patients treated with any Adalimumab Biosimilar (Amgevita, Hyrimioz, Idacio, Imraldi etc) in the last 3 months, how many patients were new to Adalimumab treatment (patients who had not been treated with any brand of Adalimumab in the past year)? If possible provide new patients numbers by department:

8 March 2022

New Adalimumab Biosimilar patients – all departments	New Adalimumab Biosimilar patients – rheumatology	New Adalimumab Biosimilar patients – dermatology	New Adalimumab Biosimilar patients – gastroenterology
	24	44	